Cargando…
Corrigendum to “Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein” [Vaccine 40(20) (2022) 2856–2868]
Autores principales: | Pouriayevali, Mohammad Hassan, Teimoori, Ali, Esmaeili, Saber, Abdoli, Asghar, Doroud, Delaram, Salehi-Vaziri, Mostafa, Shahali, Maryam, Kadkhodazadeh, Maryam, Sabouni, Talieh, Ali Khosravi, Mohammad, Panahi, Mohammad, Khoshroo, Fereidoon, Bahmanjeh, Anahita, Valdes-Balbin, Yury, Garcia-Rivera, Dagmar, Verez-Bencomo, Vicente, Biglari, Alireza, Baesi, Kazem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613972/ https://www.ncbi.nlm.nih.gov/pubmed/36374711 http://dx.doi.org/10.1016/j.vaccine.2022.10.019 |
Ejemplares similares
-
Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein
por: Pouriayevali, Mohammad Hassan, et al.
Publicado: (2022) -
rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012) -
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report
por: Naghashzadeh, Farah, et al.
Publicado: (2022) -
Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)